KalVista Pharmaceuticals Brings Expertise to New European Consortium Focused on the Discovery and Development of Novel Eye Therapeutics
Published: Sep 25, 2013
SOUTHAMPTON, England, September 25, 2013 — /PRNewswire/ --
Consortium supported by EU Seventh Framework Programme
KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), is joining a group of academic and industry researchers to undertake a project known as '3D-NET' ('Drug Discovery and Development of Novel Eye Therapeutics'). The four-year project seeks to enable the development of new drugs for the treatment of ocular disease associated with inflammation, neovascularisation, edema and degeneration, through the complementary capabilities of the partners. The project will be funded through a €1.66 million Marie Curie Industry-Academia Pathways and Partnerships (IAPP) grant award from the EU Seventh Framework Programme (612218/3D-NET).
Help employers find you! Check out all the jobs and post your resume.